- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03899298
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be ongoing for patient inclusion and data acquisition. Patients who have Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions will be included.
The study has been approved by an Alion accredited Institutional Review Board, Solutions IRB, as of March 2019.
Depending on the condition, patients may receive a series of therapies via one or more of the following methods: intravenous, injection, intra-nasal and/or nebulizer. R3 has several "best practice" therapy protocols that participating practices will follow. Should a patient have conditions that fall into more than one condition category, he or she can still be included with the protocols being received for each condition(s).
Here is a specific administration for each condition category:
- Orthopedic Condition = Injection
- Neurologic Disease = IV Infusion and Intranasal Procedure. The exception is with Peripheral Neuropathy, where participants receive a series of injections along with an IV Infusion Procedure.
- Urologic = Injection
- Autoimmune = IV Infusion
- Cardiac = IV Infusion
- Pulmonary = IV Infusion plus Nebulizer
- Renal = IV Infusion
Pre, Intra and Post procedure data acquisition will occur at various time frames up to 10 years. Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months, 36 months and then on average each year, up to 10 years. Patients will pay for procedures, and no randomization will occur.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: David L Greene, MD, MBA
- Phone Number: (844) 438-7836
- Email: info@r3stemcell.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 and over.
- Ability to attend follow up visits or at least converse on phone or complete email follow up forms.
- Competent to understand the study protocol and provide voluntary informed consent.
- Patients with any of the following conditions: Arthritis (Degenerative, Rheumatoid, Psoriatic, Lupus, Gout), Sports or Overuse Injuries (e.g. Rotator Cuff injury, Tennis Elbow), Chronic Kidney Disease (may be on dialysis), Back/Neck Pain, Erectile Dysfunction, Peyronie's Disease, Alzheimer's Disease, Parkinson's Disease, Neuropathy, Post-Stroke, Post-Concussion Syndrome, COPD, Emphysema, Pulmonary Fibrosis, Post myocardial infarction (at least 6 months out), Cardiomyopathy, Congestive Heart Failure.
Exclusion Criteria:
- Active Cancer
- Pregnancy, Lactating
- Severe Clotting disorder
- Myocardial Infarction less than six months ago.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Amniotic and Umbilical Cord Tissue for Autoimmune Conditions
Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for autoimmune conditions.
Outcomes will be compared to the literature results of the current gold standard for several conditions.
|
Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition.
Protocols include options for IV, Injection, Intranasal and/or Nebulizer.
Other Names:
|
EXPERIMENTAL: Amniotic and Umbilical Cord Tissue for Orthopedic Conditions
Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for orthopedic conditions.
Outcomes will be compared to the literature results of the current gold standard for several conditions.
|
Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition.
Protocols include options for IV, Injection, Intranasal and/or Nebulizer.
Other Names:
|
EXPERIMENTAL: Amniotic and Umbilical Cord Tissue for Neurologic Conditions
Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for neurologic conditions.
Outcomes will be compared to the literature results of the current gold standard for several conditions.
|
Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition.
Protocols include options for IV, Injection, Intranasal and/or Nebulizer.
Other Names:
|
EXPERIMENTAL: Amniotic and Umbilical Cord Tissue for Urologic Conditions
Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for urologic conditions.
Outcomes will be compared to the literature results of the current gold standard for several conditions.
|
Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition.
Protocols include options for IV, Injection, Intranasal and/or Nebulizer.
Other Names:
|
EXPERIMENTAL: Amniotic and Umbilical Cord Tissue for Cardiac Conditions
Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for cardiac conditions.
Outcomes will be compared to the literature results of the current gold standard for several conditions.
|
Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition.
Protocols include options for IV, Injection, Intranasal and/or Nebulizer.
Other Names:
|
EXPERIMENTAL: Amniotic and Umbilical Cord Tissue for Renal Conditions
Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for renal conditions.
Outcomes will be compared to the literature results of the current gold standard for several conditions.
|
Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition.
Protocols include options for IV, Injection, Intranasal and/or Nebulizer.
Other Names:
|
EXPERIMENTAL: Amniotic and Umbilical Cord Tissue for Pulmonary Conditions
Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for pulmonary conditions.
Outcomes will be compared to the literature results of the current gold standard for several conditions.
|
Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition.
Protocols include options for IV, Injection, Intranasal and/or Nebulizer.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disabilities of Arm, Shoulder, Hand Questionnaire (DASH)
Time Frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Upper Extremity Outcome Instrument
|
Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Sexual Health Inventory for Men Questionnaire (SHIM)
Time Frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Erectile Function Questionnaire.
Scoring exists from 0 to 25.
The lower the score, the more severe the Erectile Dysfunction.
|
Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Kidney Disease and Quality of Life Questionnaire (KDQOL)
Time Frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Renal Function Outcome Instrument.
Raw, precoded numeric values for 36 items are transformed linearly to a 0 to 100 range, with higher scores reflecting better quality of life.
|
Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Assessment of Quality of Life Questionnaire (AQOL)
Time Frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
General Health Outcome Instrument.
Each instrument is used to derive a simple psychometric score for health related quality of life (HRQoL) and to provide profile scores on the different dimensions or items of the descriptive systems.
The score is derived by adding the unweighted response order of each question, with a lower score denoting a better quality of life.
|
Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Clinical Chronic Obstructive Pulmonary Disease Questionnaire
Time Frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
COPD Outcome Instrument.
Items are scored on a Likert scale (range 0-60).
Higher scores indicate a worse health status.
|
Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Mini Mental State Examination (MMSE)
Time Frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Memory Outcome Instrument.
The maximum MMSE score is 30 points.
The lower the score, the more severe the dementia.
|
Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
O'Leary/Sant Questionnaire
Time Frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Voiding and Pain Indices.
Possible score of 0-20 with higher scores denoting better function.
|
Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Oswestry Low Back Pain Disability Questionnaire
Time Frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Low Back Pain Outcome Instrument.
Possible score of 0-100 with lower scores denoting better function.
|
Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Western Ontario and McMaster Osteoarthritis Index (WOMAC)
Time Frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Arthritis Outcome Instrument.
Individual question scores are then summed to form a raw score ranging from 0 (worst) to 96 (best).
|
Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: David Greene, MD, MBA, R3 Stem Cell
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Brain Diseases
- Central Nervous System Diseases
- Immune System Diseases
- Neurocognitive Disorders
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Sexual Dysfunctions, Psychological
- Sexual Dysfunction, Physiological
- Kidney Diseases
- Disease
- Peripheral Nervous System Diseases
- Renal Insufficiency
- Nervous System Diseases
- Alzheimer Disease
- Erectile Dysfunction
- Cardiomyopathies
- Musculoskeletal Diseases
- Autoimmune Diseases
- Urologic Diseases
Other Study ID Numbers
- #2018/10/11
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on Amniotic and Umbilical Cord Tissue Procedure
-
Amniox Medical, Inc.TerminatedFoot Ulcer, DiabeticUnited States
-
Translational BiosciencesWithdrawnOsteoarthritis of the KneePanama
-
Ottawa Hospital Research InstituteCanadian Institutes of Health Research (CIHR); Stem Cell Network; Ontario Institute...RecruitingBronchopulmonary DysplasiaCanada
-
Uppsala University HospitalUppsala County Council, SwedenUnknown
-
Wuhan Optics Valley Vcanbiopharma Co., Ltd.RecruitingIdiopathic Pulmonary FibrosisChina
-
Genesis LimitedTerminatedMultiple Sclerosis, Relapsing-RemittingTrinidad and Tobago
-
Restem, LLC.CompletedCovid19 | Corona Virus Infection | ARDS | SARS-CoV Infection | CoronavirusUnited States
-
Novo Cellular Medicine Institute LLPUnknownMultiple Sclerosis, Relapsing-RemittingTrinidad and Tobago
-
Biosplice Therapeutics, Inc.TerminatedOsteoarthritis of the KneeUnited States